Trade Alimera Sciences, Inc. - ALIM CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.24 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025457% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003235% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 2.49 |
Open* | 2.51 |
1-Year Change* | -55.81% |
Day's Range* | 2.38 - 2.51 |
52 wk Range | 1.30-7.92 |
Average Volume (10 days) | 107.41K |
Average Volume (3 months) | 13.10M |
Market Cap | 19.10M |
P/E Ratio | -100.00K |
Shares Outstanding | 7.40M |
Revenue | 55.78M |
EPS | -2.44 |
Dividend (Yield %) | N/A |
Beta | 1.39 |
Next Earnings Date | Jul 25, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jun 9, 2023 | 2.41 | -0.03 | -1.23% | 2.44 | 2.52 | 2.35 |
Jun 8, 2023 | 2.49 | -0.15 | -5.68% | 2.64 | 2.65 | 2.41 |
Jun 7, 2023 | 2.62 | -0.05 | -1.87% | 2.67 | 2.71 | 2.57 |
Jun 6, 2023 | 2.75 | 0.10 | 3.77% | 2.65 | 2.89 | 2.64 |
Jun 5, 2023 | 2.71 | 0.18 | 7.11% | 2.53 | 2.80 | 2.53 |
Jun 2, 2023 | 2.57 | 0.06 | 2.39% | 2.51 | 2.66 | 2.50 |
Jun 1, 2023 | 2.52 | -0.08 | -3.08% | 2.60 | 2.60 | 2.51 |
May 31, 2023 | 2.67 | 0.19 | 7.66% | 2.48 | 2.67 | 2.48 |
May 30, 2023 | 2.52 | 0.05 | 2.02% | 2.47 | 2.55 | 2.47 |
May 26, 2023 | 2.49 | 0.08 | 3.32% | 2.41 | 2.52 | 2.35 |
May 25, 2023 | 2.48 | -0.02 | -0.80% | 2.50 | 2.51 | 2.37 |
May 24, 2023 | 2.41 | 0.23 | 10.55% | 2.18 | 2.42 | 2.14 |
May 23, 2023 | 2.32 | -0.19 | -7.57% | 2.51 | 2.55 | 2.21 |
May 22, 2023 | 2.45 | 0.28 | 12.90% | 2.17 | 2.72 | 2.15 |
May 19, 2023 | 2.23 | 0.12 | 5.69% | 2.11 | 2.30 | 2.02 |
May 18, 2023 | 2.34 | -0.26 | -10.00% | 2.60 | 3.05 | 2.26 |
May 17, 2023 | 1.93 | 0.11 | 6.04% | 1.82 | 1.94 | 1.78 |
May 16, 2023 | 1.79 | 0.21 | 13.29% | 1.58 | 1.92 | 1.58 |
May 15, 2023 | 1.57 | -0.03 | -1.88% | 1.60 | 1.68 | 1.56 |
May 12, 2023 | 1.56 | -0.05 | -3.11% | 1.61 | 1.64 | 1.55 |
Alimera Sciences, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, July 12, 2023 | ||
Time (UTC) 13:30 | Country US
| Event Alimera Sciences Inc Annual Shareholders Meeting Alimera Sciences Inc Annual Shareholders MeetingForecast -Previous - |
Tuesday, July 25, 2023 | ||
Time (UTC) 12:30 | Country US
| Event Q2 2023 Alimera Sciences Inc Earnings Release Q2 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
Monday, November 13, 2023 | ||
Time (UTC) 13:30 | Country US
| Event Q3 2023 Alimera Sciences Inc Earnings Release Q3 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
Revenue | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
Cost of Revenue, Total | 7.977 | 7.03 | 6.941 | 6.626 | 4.308 |
Gross Profit | 46.152 | 51.999 | 43.879 | 47.317 | 42.291 |
Total Operating Expense | 65.769 | 57.438 | 51.321 | 59.217 | 58.035 |
Selling/General/Admin. Expenses, Total | 38.858 | 35.843 | 32.036 | 38.958 | 38.042 |
Research & Development | 16.228 | 13.778 | 9.668 | 10.992 | 11.274 |
Depreciation / Amortization | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
Unusual Expense (Income) | 0 | -1.792 | 0 | 1.766 | |
Operating Income | -11.64 | 1.591 | -0.501 | -5.274 | -11.436 |
Interest Income (Expense), Net Non-Operating | -5.789 | -4.997 | -4.906 | -4.953 | -4.84 |
Net Income Before Taxes | -18.079 | -3.934 | -5.407 | -10.227 | -16.276 |
Net Income After Taxes | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Net Income Before Extra. Items | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Net Income | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Income Available to Common Excl. Extra. Items | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Income Available to Common Incl. Extra. Items | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Diluted Net Income | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Diluted Weighted Average Shares | 6.99685 | 6.59524 | 5.11766 | 4.7702 | 5.91587 |
Diluted EPS Excluding Extraordinary Items | -2.58788 | -0.6629 | -1.04325 | -2.18921 | 3.71002 |
Diluted Normalized EPS | -2.58788 | -0.83951 | -1.04325 | -2.18921 | 3.90406 |
Other Operating Expenses, Total | |||||
Total Extraordinary Items | 0 | 0 | |||
Total Adjustments to Net Income | 0 | 38.33 | |||
Other, Net | -0.65 | -0.528 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
Revenue | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
Cost of Revenue, Total | 2.028 | 2.125 | 2.006 | 2.166 | 1.68 |
Gross Profit | 11.518 | 11.904 | 11.592 | 12.438 | 10.218 |
Total Operating Expense | 16.848 | 16.137 | 17.009 | 16.578 | 16.045 |
Selling/General/Admin. Expenses, Total | 9.975 | 9.099 | 9.856 | 9.81 | 10.093 |
Research & Development | 4.164 | 4.23 | 4.483 | 3.932 | 3.583 |
Depreciation / Amortization | 0.681 | 0.683 | 0.664 | 0.67 | 0.689 |
Operating Income | -3.302 | -2.108 | -3.411 | -1.974 | -4.147 |
Interest Income (Expense), Net Non-Operating | -1.68 | -1.621 | -1.567 | -1.345 | -1.256 |
Net Income Before Taxes | -4.968 | -3.781 | -5.245 | -3.098 | -5.955 |
Net Income After Taxes | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Net Income Before Extra. Items | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Net Income | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Income Available to Common Excl. Extra. Items | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Income Available to Common Incl. Extra. Items | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Diluted Net Income | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Diluted Weighted Average Shares | 7.03223 | 7.00032 | 6.99658 | 6.99971 | 6.99074 |
Diluted EPS Excluding Extraordinary Items | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
Unusual Expense (Income) | 0 | 0 | 0 | ||
Other, Net | 0.014 | -0.052 | -0.267 | 0.221 | -0.552 |
Total Adjustments to Net Income | -0.014 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 29.413 | 42.16 | 34.906 | 32.745 | 34.848 |
Cash and Short Term Investments | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
Cash & Equivalents | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
Total Receivables, Net | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
Accounts Receivable - Trade, Net | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
Total Inventory | 1.605 | 2.679 | 2.746 | 1.39 | 2.405 |
Prepaid Expenses | 2.892 | 3.809 | 3.718 | 2.565 | 2.109 |
Other Current Assets, Total | 0.03 | 0.034 | 0.034 | 0.033 | 0.032 |
Total Assets | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
Property/Plant/Equipment, Total - Net | 3.92 | 4.493 | 2.358 | 2.047 | 1.355 |
Property/Plant/Equipment, Total - Gross | 7.981 | 7.923 | 6.305 | 5.858 | 4.967 |
Accumulated Depreciation, Total | -4.061 | -3.43 | -3.947 | -3.881 | -3.612 |
Intangibles, Net | 8.957 | 10.897 | 12.838 | 14.783 | 16.723 |
Other Long Term Assets, Total | 0.129 | 0.137 | 0.753 | 0.734 | 1.182 |
Total Current Liabilities | 39.732 | 12.592 | 12.348 | 12.048 | 10.234 |
Accounts Payable | 10.088 | 8.706 | 7.461 | 7.077 | 6.355 |
Accrued Expenses | 3.998 | 3.617 | 3.197 | 4.716 | 3.643 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 25.646 | 0.269 | 1.69 | 0.255 | 0.236 |
Other Current Liabilities, Total | |||||
Total Liabilities | 63.41 | 61.125 | 58.833 | 54.754 | 51.386 |
Total Long Term Debt | 18.683 | 43.08 | 42.922 | 38.752 | 38.178 |
Long Term Debt | 18.683 | 43.08 | 42.408 | 38.658 | 37.873 |
Capital Lease Obligations | 0.514 | 0.094 | 0.305 | ||
Other Liabilities, Total | 4.995 | 5.453 | 3.563 | 3.954 | 2.974 |
Total Equity | -20.808 | -2.605 | -7.978 | -4.445 | 2.722 |
Preferred Stock - Non Redeemable, Net | 19.227 | 19.227 | 19.227 | 30.344 | 30.344 |
Common Stock | 0.07 | 0.069 | 0.057 | 0.05 | 0.701 |
Additional Paid-In Capital | 378.238 | 377.229 | 365.83 | 350.117 | 346.108 |
Retained Earnings (Accumulated Deficit) | -415.388 | -397.281 | -392.539 | -383.863 | -373.42 |
Other Equity, Total | -2.955 | -1.849 | -0.553 | -1.093 | -1.011 |
Total Liabilities & Shareholders’ Equity | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
Total Common Shares Outstanding | 6.99551 | 6.93515 | 5.71937 | 4.96595 | 4.67193 |
Total Preferred Shares Outstanding | 0.6 | 0.6 | 0.6 | 0.61015 | 0.61015 |
Long Term Investments | 0.183 | 0.833 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 35.675 | 29.413 | 29.76 | 33.073 | 34.753 |
Cash and Short Term Investments | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
Cash & Equivalents | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
Total Receivables, Net | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
Accounts Receivable - Trade, Net | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
Total Inventory | 1.215 | 1.605 | 1.786 | 1.656 | 2.452 |
Prepaid Expenses | 2.91 | 2.892 | 3.29 | 3.208 | 3.546 |
Other Current Assets, Total | 0.031 | 0.03 | 0.028 | 0.031 | 0.033 |
Total Assets | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
Property/Plant/Equipment, Total - Net | 3.757 | 3.92 | 3.87 | 3.938 | 4.343 |
Intangibles, Net | 8.479 | 8.957 | 9.446 | 9.935 | 10.419 |
Other Long Term Assets, Total | 0.131 | 0.129 | 0.118 | 0.126 | 0.134 |
Total Current Liabilities | 14.173 | 39.732 | 34.01 | 25.431 | 17.006 |
Accounts Payable | 9.669 | 10.088 | 8.706 | 7.614 | 6.604 |
Accrued Expenses | 4.241 | 3.998 | 3.661 | 3.316 | 3.046 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.263 | 25.646 | 21.643 | 14.501 | 7.356 |
Total Liabilities | 67.155 | 63.41 | 61.507 | 59.909 | 58.534 |
Total Long Term Debt | 44.312 | 18.683 | 22.492 | 29.297 | 36.245 |
Long Term Debt | 44.152 | 18.683 | 22.492 | 29.297 | 36.245 |
Capital Lease Obligations | 0.16 | ||||
Other Liabilities, Total | 8.67 | 4.995 | 5.005 | 5.181 | 5.283 |
Total Equity | -18.916 | -20.808 | -18.078 | -12.335 | -8.603 |
Preferred Stock - Non Redeemable, Net | 7.728 | 19.227 | 19.227 | 19.227 | 19.227 |
Common Stock | 0.074 | 0.07 | 0.07 | 0.07 | 0.07 |
Additional Paid-In Capital | 378.146 | 378.238 | 378.005 | 377.847 | 377.541 |
Retained Earnings (Accumulated Deficit) | -402.081 | -415.388 | -411.608 | -406.351 | -403.236 |
Other Equity, Total | -2.783 | -2.955 | -3.772 | -3.128 | -2.205 |
Total Liabilities & Shareholders’ Equity | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
Total Common Shares Outstanding | 7.39159 | 6.99551 | 6.99802 | 6.99546 | 6.99265 |
Total Preferred Shares Outstanding | 0.012 | 0.6 | 0.6 | 0.6 | 0.6 |
Long Term Investments | 0.197 | 0.183 | 0.235 | 0.502 | 0.282 |
Other Current Liabilities, Total |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Cash From Operating Activities | -9.975 | -3.224 | -2.193 | -4.152 | -11.553 |
Cash From Operating Activities | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
Deferred Taxes | 0.116 | 0.61 | 0.031 | 0.454 | -0.653 |
Non-Cash Items | 2.621 | -0.692 | 1.829 | 3.377 | 7.084 |
Cash Taxes Paid | 0.232 | 0.112 | 0.11 | 0.239 | 0.239 |
Cash Interest Paid | 4.489 | 4.302 | 4.556 | 4.419 | 3.571 |
Changes in Working Capital | 2.689 | -1.349 | -1.39 | -0.181 | -4.247 |
Cash From Investing Activities | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
Capital Expenditures | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
Cash From Financing Activities | -0.302 | 9.823 | 3.882 | 0.869 | 0.95 |
Financing Cash Flow Items | -0.113 | 0 | -0.019 | -2.227 | -3.808 |
Issuance (Retirement) of Stock, Net | 0.1 | 10.044 | 0.049 | 0.902 | 0.085 |
Issuance (Retirement) of Debt, Net | -0.289 | -0.221 | 3.852 | 2.194 | 4.673 |
Foreign Exchange Effects | -0.708 | -0.676 | 0.714 | -0.159 | -0.248 |
Net Change in Cash | -11.24 | 5.302 | 1.783 | -3.616 | -11.026 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.968 | -18.107 | -14.327 | -9.07 | -5.955 |
Cash From Operating Activities | -2.209 | -9.975 | -9.724 | -7.811 | -6.213 |
Cash From Operating Activities | 0.681 | 2.706 | 2.023 | 1.359 | 0.689 |
Non-Cash Items | 0.507 | 2.621 | 2.095 | 1.318 | 1.027 |
Cash Taxes Paid | 0 | 0.232 | 0.224 | 0.182 | 0.018 |
Cash Interest Paid | 1.354 | 4.489 | 3.253 | 2.145 | 1.061 |
Changes in Working Capital | 1.571 | 2.689 | 0.485 | -1.418 | -1.974 |
Cash From Investing Activities | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
Capital Expenditures | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
Cash From Financing Activities | 9.998 | -0.302 | -0.109 | -0.164 | -0.062 |
Financing Cash Flow Items | -3.123 | -0.113 | |||
Issuance (Retirement) of Debt, Net | 2.373 | -0.289 | -0.164 | -0.204 | -0.062 |
Foreign Exchange Effects | 0.033 | -0.708 | -0.998 | -0.638 | -0.141 |
Net Change in Cash | 7.813 | -11.24 | -11.002 | -8.654 | -6.565 |
Issuance (Retirement) of Stock, Net | 10.748 | 0.1 | 0.055 | 0.04 | |
Deferred Taxes | 0.116 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 22.4131 | 1659654 | 1401901 | 2023-05-17 | MED |
Ocumension Therapeutics | Corporation | 15.4621 | 1144945 | 0 | 2023-04-24 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 8.9243 | 660832 | 0 | 2023-03-31 | MED |
Caligan Partners, LP | Hedge Fund | 6.4657 | 478777 | 0 | 2023-05-17 | MED |
Eiswirth (Richard S Jr) | Individual Investor | 4.3555 | 322518 | 500 | 2023-04-24 | LOW |
HOOPP Investment Management | Pension Fund | 3.3762 | 250000 | 0 | 2023-03-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0071 | 148624 | 0 | 2023-03-31 | LOW |
Ashman Philip | Individual Investor | 1.8004 | 133315 | 0 | 2023-04-24 | MED |
Holland (David R) | Individual Investor | 1.4704 | 108880 | 500 | 2023-04-24 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.3693 | 101394 | -1100 | 2023-03-31 | HIGH |
Skibsted (Russell L) | Individual Investor | 1.0196 | 75500 | 58000 | 2023-03-26 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5167 | 38262 | 0 | 2023-03-31 | LOW |
Jones (John Philip) | Individual Investor | 0.4347 | 32186 | 372 | 2022-10-31 | |
Millennium Management LLC | Hedge Fund | 0.3884 | 28762 | 16799 | 2023-03-31 | HIGH |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.2639 | 19542 | 0 | 2023-03-31 | MED |
Bridgeway Capital Management, LLC | Investment Advisor | 0.2471 | 18300 | 0 | 2023-03-31 | |
Perritt Capital Management, Inc. | Investment Advisor | 0.2431 | 18000 | 0 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.175 | 12962 | 438 | 2023-03-31 | LOW |
J.P. Morgan Securities LLC | Research Firm | 0.14 | 10364 | 9838 | 2023-03-31 | MED |
Snisarenko (John) | Individual Investor | 0.135 | 10000 | 0 | 2023-04-24 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group535K+
Traders
87K+
Active clients monthly
$113M+
Monthly investing volume
$64M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Alimera Sciences, Inc. Company profile
About Alimera Sciences Inc
Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Alimera Sciences Inc revenues increased 16% to $59M. Net loss decreased 18% to $4.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects DEPRECIATION AND AMORTIZATION decrease of 4% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.04 to -$0.66.
Equity composition
Common Stock $.01 Par, 05/11, 100M auth., 31,348,197 issd. IPO:TBA. Insider owns 2.06%.
Industry: | Biopharmaceuticals |
Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US
Income Statement
- Annual
- Quarterly
News

USD/TRY forecast: Turkish lira under pressure from high inflation and low rates
We look at some of the latest USD/TRY predictions as the Turkish lira hits record lows.
17:07, 1 June 2023
Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?
Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?
07:46, 31 May 2023
Google stock forecast 2023-2025
What is the outlook for the tech giant, following a tumultuous 2022?
18:02, 30 May 2023
USD forecast: DXY slides in risk-off market sentiment
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
16:10, 24 May 2023
Oil price forecast: Will WTI and Brent regain momentum in 2023?
Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.
11:38, 22 May 2023
Weekly Roundup: Tech stocks lead the way
US stocks push higher as risk appetite surges despite the uncertainty
13:39, 19 May 2023
USD/JPY continues to build higher towards 138
USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher
11:50, 17 May 2023People also watch
Still looking for a broker you can trust?
Join the 535.000+ traders worldwide that chose to trade with Capital.com